According to a new report published by Introspective Market Research, titled, Global Third Generation Sequencing Market by Technology, Application, End-User, and Region, The Global Third Generation Sequencing Market Size Was Valued at USD 10.10 Billion in 2023 and is Projected to Reach USD 50.57 Billion by 2032, Growing at a CAGR of 19.60% from 2024 to 2032. The Global Third Generation Sequencing Market is experiencing rapid expansion due to its transformative impact on genomic research and clinical diagnostics. Third-generation sequencing (TGS), also referred to as long-read sequencing, is a cutting-edge technology that enables real-time DNA sequencing with longer read lengths, higher accuracy, and faster turnaround compared to traditional sequencing methods. These platforms, including nanopore and single-molecule real-time (SMRT) sequencing, are capable of detecting complex genetic variations and epigenetic modifications with precision.
Unlike second-generation sequencing, TGS does not require PCR amplification, thereby reducing bias and providing clearer insight into structural variants and repetitive regions of the genome. This technology is increasingly adopted in fields like oncology, personalized medicine, microbiology, transcriptomics, and agricultural genomics. As the cost of sequencing continues to decline and demand for comprehensive, real-time genetic analysis grows, third-generation sequencing is becoming an essential tool across academic, clinical, and commercial settings.
The Global Third Generation Sequencing Market is segmented into Technology, Application, and End-User. By Technology, the market is categorized into (Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, and Others). By Application, the market is categorized into (Oncology, Clinical Investigation, Human Genomics, Microbiology, and Others). By End-User, the market is categorized into (Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others).
A major growth driver for the Third Generation Sequencing Market is the increasing demand for precise, real-time genetic data in clinical diagnostics and personalized medicine. As healthcare shifts toward individualized treatment plans, clinicians and researchers are relying on TGS technologies to identify complex genetic mutations, structural variations, and epigenetic markers that were previously undetectable. The ability of TGS platforms to deliver rapid and high-resolution data supports early disease diagnosis, especially in oncology and rare genetic disorders, fueling market growth.
The integration of third-generation sequencing with artificial intelligence and machine learning tools presents a major market opportunity. These technologies together enhance sequencing accuracy, reduce analysis time, and enable real-time decision-making in clinical and research environments. Additionally, expanding government and private sector investments in genomic research and the increasing need for advanced diagnostic tools in emerging markets open new avenues for TGS adoption in precision health initiatives and large-scale population genomics projects.
Global Third Generation Sequencing Market, Segmentation
The Global Third Generation Sequencing Market is segmented on the basis of Technology, Application, and End-User.
Technology
The Technology segment is further classified into Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, and Others. Among these, the SMRT sequencing sub-segment accounted for the highest market share in 2023. SMRT sequencing enables real-time analysis of long DNA strands at single-molecule resolution, allowing accurate detection of structural variants, methylation patterns, and transcript isoforms. Its high throughput and longer read lengths make it ideal for complex genome assemblies and are widely used in cancer genomics and microbial research.
Application
The Application segment is further classified into Oncology, Clinical Investigation, Human Genomics, Microbiology, and Others. Among these, the Oncology sub-segment accounted for the highest market share in 2023. TGS technologies are increasingly used in oncology to detect rare mutations, analyze tumor heterogeneity, and guide personalized cancer treatments. Their ability to accurately sequence full-length genes, fusion transcripts, and DNA methylation sites enhances precision in cancer diagnostics and therapy planning, making them indispensable in clinical oncology workflows.
Some of The Leading/Active Market Players Are–
- Pacific Biosciences (USA)
- Oxford Nanopore Technologies (UK)
- Illumina Inc. (USA)
- Thermo Fisher Scientific (USA)
- BGI Genomics Co. Ltd. (China)
- Agilent Technologies (USA)
- QIAGEN N.V. (Netherlands)
- Roche Holding AG (Switzerland)
- Bio-Rad Laboratories (USA)
- Genapsys Inc. (USA)
- Stratos Genomics (USA)
- Nabsys Inc. (USA)
- Direct Genomics (China)
- …and other active players.
Key Industry Developments
In June 2024, Pacific Biosciences launched its next-generation Revio sequencing system for high-throughput long-read sequencing.
The new platform supports over 1,000 whole human genomes per year with improved affordability and data accuracy. This development accelerates large-scale human genomics and expands access to comprehensive genomic data for researchers and clinical labs worldwide, strengthening PacBio’s leadership in the long-read sequencing market.
According to a new report published by Introspective Market Research, titled, Global Third Generation Sequencing Market by Technology, Application, End-User, and Region, The Global Third Generation Sequencing Market Size Was Valued at USD 10.10 Billion in 2023 and is Projected to Reach USD 50.57 Billion by 2032, Growing at a CAGR of 19.60% from 2024 to 2032. The Global Third Generation Sequencing Market is experiencing rapid expansion due to its transformative impact on genomic research and clinical diagnostics. Third-generation sequencing (TGS), also referred to as long-read sequencing, is a cutting-edge technology that enables real-time DNA sequencing with longer read lengths, higher accuracy, and faster turnaround compared to traditional sequencing methods. These platforms, including nanopore and single-molecule real-time (SMRT) sequencing, are capable of detecting complex genetic variations and epigenetic modifications with precision.
Unlike second-generation sequencing, TGS does not require PCR amplification, thereby reducing bias and providing clearer insight into structural variants and repetitive regions of the genome. This technology is increasingly adopted in fields like oncology, personalized medicine, microbiology, transcriptomics, and agricultural genomics. As the cost of sequencing continues to decline and demand for comprehensive, real-time genetic analysis grows, third-generation sequencing is becoming an essential tool across academic, clinical, and commercial settings.
The Global Third Generation Sequencing Market is segmented into Technology, Application, and End-User. By Technology, the market is categorized into (Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, and Others). By Application, the market is categorized into (Oncology, Clinical Investigation, Human Genomics, Microbiology, and Others). By End-User, the market is categorized into (Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others).
A major growth driver for the Third Generation Sequencing Market is the increasing demand for precise, real-time genetic data in clinical diagnostics and personalized medicine. As healthcare shifts toward individualized treatment plans, clinicians and researchers are relying on TGS technologies to identify complex genetic mutations, structural variations, and epigenetic markers that were previously undetectable. The ability of TGS platforms to deliver rapid and high-resolution data supports early disease diagnosis, especially in oncology and rare genetic disorders, fueling market growth.
The integration of third-generation sequencing with artificial intelligence and machine learning tools presents a major market opportunity. These technologies together enhance sequencing accuracy, reduce analysis time, and enable real-time decision-making in clinical and research environments. Additionally, expanding government and private sector investments in genomic research and the increasing need for advanced diagnostic tools in emerging markets open new avenues for TGS adoption in precision health initiatives and large-scale population genomics projects.
Global Third Generation Sequencing Market, Segmentation
The Global Third Generation Sequencing Market is segmented on the basis of Technology, Application, and End-User.
Technology
The Technology segment is further classified into Single Molecule Real Time (SMRT) Sequencing, Nanopore Sequencing, and Others. Among these, the SMRT sequencing sub-segment accounted for the highest market share in 2023. SMRT sequencing enables real-time analysis of long DNA strands at single-molecule resolution, allowing accurate detection of structural variants, methylation patterns, and transcript isoforms. Its high throughput and longer read lengths make it ideal for complex genome assemblies and are widely used in cancer genomics and microbial research.
Application
The Application segment is further classified into Oncology, Clinical Investigation, Human Genomics, Microbiology, and Others. Among these, the Oncology sub-segment accounted for the highest market share in 2023. TGS technologies are increasingly used in oncology to detect rare mutations, analyze tumor heterogeneity, and guide personalized cancer treatments. Their ability to accurately sequence full-length genes, fusion transcripts, and DNA methylation sites enhances precision in cancer diagnostics and therapy planning, making them indispensable in clinical oncology workflows.
Some of The Leading/Active Market Players Are–
- Pacific Biosciences (USA)
- Oxford Nanopore Technologies (UK)
- Illumina Inc. (USA)
- Thermo Fisher Scientific (USA)
- BGI Genomics Co. Ltd. (China)
- Agilent Technologies (USA)
- QIAGEN N.V. (Netherlands)
- Roche Holding AG (Switzerland)
- Bio-Rad Laboratories (USA)
- Genapsys Inc. (USA)
- Stratos Genomics (USA)
- Nabsys Inc. (USA)
- Direct Genomics (China)
…and other active players.
Key Industry Developments
In June 2024, Pacific Biosciences launched its next-generation Revio sequencing system for high-throughput long-read sequencing.
The new platform supports over 1,000 whole human genomes per year with improved affordability and data accuracy. This development accelerates large-scale human genomics and expands access to comprehensive genomic data for researchers and clinical labs worldwide, strengthening PacBio’s leadership in the long-read sequencing market.
In August 2024, Oxford Nanopore Technologies entered a partnership with the European Precision Medicine Consortium to supply real-time sequencing solutions.
The collaboration focuses on integrating Nanopore’s sequencing devices in population genomics and rare disease screening programs across Europe. This partnership aims to expand access to portable, rapid sequencing solutions and foster innovation in precision health and clinical genomics at a continental scale.
Key Findings of the Study
- SMRT sequencing led the technology segment in 2023 due to high accuracy and longer read lengths.
- Oncology emerged as the top application, driven by the growing need for precision cancer diagnostics.
- North America holds a dominant regional share due to established genomic infrastructure.
- Market growth is driven by increasing adoption in clinical diagnostics and AI-integrated sequencing tools.
